Rigel Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Net Income Per Share (Tables)

Net Income Per Share (Tables)

3 Months Ended

Mar. 31, 2021

Schedule of computation of basic and diluted earnings per share

The following table sets forth the computation of basic and diluted earnings per share (in thousands except per share amounts):


	Three Months Ended
	March 31,
	2021		2020
EPS Numerator:
Net income	$	39,500	$	21,243
EPS Denominator—Basic:
Weighted-average common shares outstanding		169,800		168,469
EPS Denominator—Diluted:
Weighted-average common shares outstanding		169,800		168,469
Dilutive effect of stock options, restricted stock units and shares under ESPP		6,269		99
Weighted-average shares outstanding and common stock equivalents		176,069		168,568

Net income per common share, basic and diluted
Basic	$	0.23	$	0.13
Diluted	$	0.22	$	0.13

Schedule of antidilutive securities

The potential shares of common stock that were excluded from the computation of diluted net income per share for the periods presented because including them would have been antidilutive are as follows: (in thousands):


	Three Months Ended
	March 31,
	2021		2020
Outstanding stock options		8,183		23,206
Restricted stock units		2		—
Total		8,185		23,206